Real-world effectiveness and drug retention rate of risankizumab in patients with psoriatic arthritis: data from the multicentre GIRRCS cohort. (PubMed, Expert Opin Biol Ther) - Sep 18, 2026 - "Estimated 18-month DRR was 59.8%. Risankizumab was associated with clinical benefit and acceptable treatment persistence, even if larger studies are needed."
Journal • Real-world evidence • Immunology • Inflammation • Inflammatory Arthritis • Pain • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL23A
|
|
Alberto Lo Gullo; Azadeh Shariat Panahi; Daniele Mauro; Eleonora Celletti; Francesca Saracino; Francesco Caso; Francesco Ciccia; Francesco Maria Mariani; Francesco Ursini; Giuliana Guggino; Ilenia Pantano; Luisa Costa; Myriam Di Penta; Paola Cipriani; Piero Ruscitti; Raffaele Scarpa; Riccardo Mattia Ricciardi; Roberto Giacomelli
|